SIMULATED MOS OF GEMCITABINE plus CARBOPLATIN +/- MAINTENANCE AVELUMAB THERAPY OR ENFORTUMAB VEDOTIN plus PEMBROLIZUMAB IN FIRST-LINE TREATMENT OF LA/MUC IN PATIENTS INELIGIBLE FOR CISPLATIN USING DISEASE MODELING Meeting Abstract

International Collaboration

cited authors

  • Galsky, M. D.; Sonpavde, G. P.; Bloudek, B.; Farrar, M.; Hepp, Z.; Timmons, J.; Powles, T.

authors

Publication Date

  • June 1, 2023

webpage

published in

category

start page

  • S26

end page

  • S27

volume

  • 26

issue

  • 6